Alimera Sciences (NASDAQ:ALIM) pared an earlier drop to 6% after it said it filed a lawsuit against ANI Pharmaceuticals (ANIP) to compel the company to close its acquisition of Alimera.

ANI Pharmaceuticals (ANIP – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Oren ...

In May, Alimera Sciences reported a whopping 70% year-on-year increase in net revenue to $23 million on the back of a 23% growth in the global end user demand. The biopharmaceuticals sales company ...

ANIP may be acquired soon with a potential offer exceeding $8 billion and contingent on FDA approval of a new drug filed in ...

Ani Pharmaceuticals ( (ANIP) ) has released its Q3 earnings. Here is a breakdown of the information Ani Pharmaceuticals presented to its ...

An implant developed by Alimera Sciences has been recommended by NICE to treat an inflammatory eye disease that can cause permanent vision loss. The UK cost-effectiveness watchdog says there is ev ...

NASDAQ ALIM opened at $5.54 on Wednesday. Alimera Sciences has a 12 month low of $2.61 and a 12 month high of $5.65. The stock has a market cap of $290.24 million, a P/E ratio of -3.53 and a beta ...

For Q3, investors will be centered on the Alimera (ALIM) acquisition following its delayed closure, and the firm’s main spotlight during the earnings call will be on the FDA warning letter ...

Piper initiated with an Overweight rating and a price target of $68. Earlier this year, ANI Pharmaceuticals acquired Alimera Sciences for $5.50 per share in cash and one non-tradable contingent ...

These forward-looking statements represent the Company’s expectations or beliefs concerning future events, including statements regarding the benefits of the acquisition of Alimera Sciences.

We also put a new, more efficient and effective capital structure in place and completed the acquisition of Alimera, which is ...

We also put a new, more efficient and effective capital structure in place and completed the acquisition of Alimera, which is highly synergistic to our Rare Disease business. We believe our proven ...